- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03243435
Sienna+MR Long-term Uptake
August 3, 2017 updated by: Cornelia Leo, Kantonsspital Baden
Feasibility of Breast MRI After Sentinel Procedure for Breast Cancer With Superparamagnetic Tracers
In a previous study in 2012/2013 patients were injected a superparamagnetic iron oxide for sentinel lymph node detection.
In this follow up study we want to investigate how much of this tracer is still detectable.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
34
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Aargau
-
Baden, Aargau, Switzerland
- Kantonsspital Baden
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
all 34 patients from the previous study are included
Description
inclusion:
- participation in previous study
- informed consent
- no contraindications for MRI scan
exclusion:
- contraindications for MRI scan
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Native 1,5 Tesla breast MRI group
From all patients a 1,5 Tesla MRI of the breast will be obtained
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
I) Analysis if the supraparamegnetic Tracer is still detectable
Time Frame: 04/2017
|
Analysis by two expert radiologists
|
04/2017
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Analysis to which degree of impairment of Imaging is detected
Time Frame: 04/2017
|
Description as "no impairment", impairment, but Interpretation of Images possible", "impairment, Image Interpretation impossible"
|
04/2017
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2016
Primary Completion (Actual)
April 1, 2017
Study Completion (Actual)
April 1, 2017
Study Registration Dates
First Submitted
July 5, 2016
First Submitted That Met QC Criteria
August 3, 2017
First Posted (Actual)
August 9, 2017
Study Record Updates
Last Update Posted (Actual)
August 9, 2017
Last Update Submitted That Met QC Criteria
August 3, 2017
Last Verified
August 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2016-00808
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer Female
-
Institut fuer FrauengesundheitNovartis Pharmaceuticals; AGO Breast Study Group e.V.RecruitingBreast Cancer | Breast Neoplasms | Advanced Breast Cancer | Breast Neoplasm Female | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor-positive Breast CancerGermany
-
Dalarna County Council, SwedenRecruitingBreast Cancer - FemaleSweden
-
Al-Quds UniversityNot yet recruitingThe Effect of Psychosocial Support on Improving Breast Cancer Patients Response to Medical TreatmentBreast Cancer - FemalePalestinian Territories
-
Oncoliq US IncRecruitingBreast Cancer Female | Breast Cancer Detection | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer With Low to Intermediate HER2 Expression | Breast Cancer - Female | Breast Cancer (Early Breast Cancer) | Breast Cancer - Ductal Carcinoma in Situ (DCIS) | Breast Cancer - Infiltrating...Argentina
-
University of Kansas Medical CenterRecruitingBreast Cancer FemaleUnited States
-
Izmir Biomedicine and Genome CenterDokuz Eylul University; Antalya Training and Research Hospital; Akdeniz University...Enrolling by invitationFemale Breast Cancer PatientsTurkey (Türkiye)
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
-
Carebot s.r.o.CompletedBreast Neoplasms | Breast Cancer Screening | Breast Cancer Detection | Breast Cancer - FemaleCzechia, Slovakia
-
Dana-Farber Cancer InstituteBreast Cancer Research FoundationNot yet recruitingBreast Cancer | Breast Carcinoma | ER Positive Breast Cancer | Breast Cancer - Female | PR-Positive Breast CancerUnited States
-
Sarah Sammons, MDStemline Therapeutics, Inc.RecruitingBreast Cancer | Metastatic Breast Cancer | Breast Cancer Female | HER2-negative Breast Cancer | HER2 Low Breast CarcinomaUnited States
Clinical Trials on Native 1,5 Tesla breast MRI
-
Assistance Publique Hopitaux De MarseilleUnknown
-
Rennes University HospitalCompletedIron Hepatic Overload | Fat Hepatic OverloadFrance
-
Radboud University Medical CenterUnknown
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMetastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the BrainUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate... and other conditionsUnited States
-
Poitiers University HospitalWithdrawn
-
University of MinnesotaCompleted
-
Johns Hopkins UniversityWithdrawnAmyotrophic Lateral Sclerosis (ALS)United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedGlioma | Metastatic Malignant Solid Neoplasm | Central Nervous System Neoplasm | Metastatic Malignant Neoplasm in the Central Nervous SystemUnited States
-
University of Texas Southwestern Medical CenterCancer Prevention Research Institute of TexasCompletedMalignant Gliomas | Astrocytomas | OligodendrogliomasUnited States